Federal Register #DEA1596

DEA Proposed Rule to Schedule Tianeptine as a Controlled Substance

This opportunity concerns a proposed DEA rulemaking, not a procurement action. - Government Buyer: - Department of Justice (DOJ) - Drug Enforcement Administration (DEA) - No OEMs or vendors are involved, as this is a regulatory action - No products or services are being requested or procured - Key Details: - DEA proposes to place tianeptine (including all isomers, esters, ethers, salts, and related forms) into Schedule I of the Controlled Substances Act - This would impose strict regulatory controls and sanctions on all activities involving tianeptine (manufacture, distribution, import/export, research, possession, etc.) - The proposal is based on findings of high abuse potential, opioid-like effects, and no accepted medical use in the U.S. - Affected entities include pharmaceutical manufacturers, wholesalers, researchers, and educational institutions - The rule is not expected to significantly impact a substantial number of small businesses - No contract, award, or procurement is associated with this notice

Description

The Drug Enforcement Administration (DEA) proposes placing the substance tianeptine, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, in Schedule I of the Controlled Substances Act. This proposed rule would impose regulatory controls and sanctions applicable to Schedule I controlled substances on persons who handle or propose to handle tianeptine, including manufacturing, distributing, importing, exporting, research, instructional activities, chemical analysis, or possession. Comments on the proposal must be submitted by August 7, 2026. The proposal is based on findings that tianeptine has a high potential for abuse and no currently accepted medical use in treatment in the United States.

View original listing